 A single-center, open label, randomized phase I study in healthy naïve adult subjects. There were three study groups; subjects were randomly assigned to groups A 12, B 12 and C 12. Group A, as a control arm of the study, had received a commercially available rabies vaccine, RABIPUR and Group B had received doses of the investigational PIKA rabies vaccine. Group C received an accelerated vaccine regimen with the investigational PIKA rabies vaccine. Group A and B followed the same vaccine regimen of 1-1-1-1, one injection on days 0, 3, 7 and 14 was administered respectively. Group C received the accelerated regimen 2-2-1, two injections on both days 0 and 3 were administered in different arms; and only one injection was administered on day 7. 